Companion Animal Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type (Dogs, Cats, Horses, Others), By Technology (Clinical Biochemistry, Clinical Chemistry Analysis, Glucose Monitoring, Blood Gas & Electrolyte Analysis, Immunodiagnostics, Hematology, Urinalysis, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.02 Billion
CAGR (2026-2031)	7.3%
Fastest Growing Segment	Dogs
Largest Market	North America
Market Size (2031)	USD 4.61 Billion

Market Overview

The Global Companion Animal Diagnostics Market is projected to grow from USD 3.02 Billion in 2025 to USD 4.61 Billion by 2031 at a 7.3% CAGR. The Global Companion Animal Diagnostics Market encompasses a range of medical tools and tests, including instruments, reagents, and consumables, utilized for detecting, monitoring, and managing diseases and health conditions in companion animals such as dogs and cats. This market's expansion is primarily driven by the increasing humanization of pets, leading to higher expenditure on veterinary care and a growing emphasis on preventive health management. Furthermore, advancements in diagnostic technologies, including point-of-care testing and molecular diagnostics, coupled with a rising prevalence of chronic and infectious diseases, significantly contribute to market growth. According to the American Pet Products Association (APPA) 2023–2024 National Pet Owners Survey, in 2023, over 65.1 million households in the US owned dogs and over 46.5 million households owned cats, illustrating the substantial pet population underpinning market demand.

Despite robust growth, a significant challenge impeding market expansion is the elevated cost associated with advanced diagnostic equipment and specialized tests. This financial barrier can restrict widespread adoption, particularly in cost-sensitive regions, and among smaller veterinary practices.

Key Market Drivers

Growing pet humanization and ownership rates significantly propel the Global Companion Animal Diagnostics Market. As pets increasingly become integral family members, owners prioritize their health and well-being, leading to a greater demand for advanced diagnostic solutions. This trend fosters a proactive approach to pet healthcare, moving beyond treating illnesses to focusing on preventive care and early disease detection. According to the American Pet Products Association (APPA)'s 2025 State of the Industry Report, released in March 2025, 94 million U.S. households owned at least one pet in 2024, marking a substantial increase from 82 million in 2023. This expansion in the pet population directly translates into a larger base of animals requiring diagnostic testing for routine check-ups, disease screening, and health monitoring, thus driving market growth for instruments, reagents, and specialized tests.

Concurrently, increasing veterinary healthcare expenditure is a critical driver for the market. Pet owners, fueled by humanization, are demonstrating a growing willingness to invest more in comprehensive veterinary care, including sophisticated diagnostic procedures. This rising financial commitment enables veterinary practices to adopt and utilize advanced diagnostic technologies. According to the American Pet Products Association (APPA), in their 2025 State of the Industry Report, U.S. pet owners spent $41.0 billion on veterinary care and product sales in 2024. Such substantial spending supports the acquisition of high-value diagnostic equipment, like advanced imaging systems and molecular diagnostic platforms, which enhance diagnostic accuracy and speed. This overall increased investment in animal health further contributes to the robust expansion of the companion animal diagnostics sector. According to the American Pet Products Association (APPA), in 2024, total U.S. pet industry expenditures reached $152 billion.

Download Free Sample Report

Key Market Challenges

The elevated cost associated with advanced diagnostic equipment and specialized tests represents a substantial impediment to the growth of the Global Companion Animal Diagnostics Market. This financial barrier limits widespread adoption of essential diagnostic tools, particularly within cost-sensitive regions and among smaller veterinary practices that may struggle with significant capital investments. Consequently, the capacity of these practices to offer a comprehensive range of advanced diagnostic services is reduced, directly constraining market expansion by narrowing the accessible user base for such products.

The impact of these costs extends to pet owners, influencing their decisions regarding recommended care. According to the American Veterinary Medical Association (AVMA) in 2026, 81% of surveyed veterinarians reported clients were more sensitive to costs than in 2024, when the figure was 72%. This increased price sensitivity directly results in diagnostics topping the list of services most frequently refused by clients, which consequently limits the demand and uptake of advanced diagnostic solutions in the market.

Key Market Trends

The shift to advanced molecular and genomic diagnostics represents a significant trend in the global companion animal diagnostics market, offering enhanced precision and earlier detection for complex conditions. These sophisticated tools enable veterinarians to identify pathogens, genetic predispositions, and specific cancer types with greater accuracy. Diagnosing diseases at a molecular level facilitates more targeted treatments and proactive health management, improving outcomes for pets. For instance, according to VolitionRx Limited, January 08, 2026, in their announcement regarding clinical data for Nu.Q® Vet Feline assay, the test detected over 80% of feline lymphomas at 100% specificity. This capability fosters greater owner confidence in advanced testing.

Concurrently, the integration of artificial intelligence and machine learning in diagnostics is reshaping veterinary practices by improving efficiency and accuracy. AI-powered platforms analyze extensive data from imaging, lab results, and patient history, aiding veterinarians in identifying subtle patterns and making informed clinical decisions. This trend proves particularly impactful in areas requiring rapid interpretation and predictive analysis. The adoption of these intelligent systems streamlines workflows, allowing veterinary professionals to dedicate more time to patient care. According to Instinct Science surveys reported by Today's Veterinary Business Staff, March 19, 2026, nearly 48% of general practices utilize AI tools, primarily for medical records and administrative support. This embrace reflects a broader industry movement towards data-driven diagnostic solutions.

Segmental Insights

The Dogs segment is demonstrating rapid expansion within the Global Companion Animal Diagnostics Market, emerging as a leading growth category. This accelerated growth is primarily attributable to the escalating humanization of pets, wherein dogs are increasingly regarded as family members, prompting owners to invest more in their well-being. Consequently, there is a heightened demand for advanced veterinary care, encompassing preventive health management, early disease detection, and routine diagnostic screenings. The rising incidence of chronic and infectious canine diseases further propels the need for comprehensive diagnostic testing, supported by continuous advancements in veterinary diagnostic technologies.

Regional Insights

North America holds a leading position in the Global Companion Animal Diagnostics Market due to several interconnected factors. The region benefits from consistently high pet ownership rates and a well-developed veterinary healthcare infrastructure, which includes numerous advanced clinics and diagnostic laboratories. This robust infrastructure is complemented by a substantial willingness among pet owners to invest in comprehensive animal health services and a strong regional focus on preventive care. The presence of key market players and continuous advancements in diagnostic technologies further contribute to the widespread adoption of innovative diagnostic solutions, firmly establishing North America's market dominance.

Recent Developments

• In January 2026, Antech™ introduced new diagnostic innovations to the companion animal market, expanding its offerings for veterinary professionals. The company launched RapidRead Dental for Feline, an artificial intelligence-powered solution specifically developed for analyzing feline dental radiographs, following its canine counterpart released in May 2025. Additionally, Antech integrated SDMA testing into its Element i+ in-house diagnostic platform. This enhancement allowed for immediate and precise assessment of kidney function directly within veterinary clinics, thereby supporting improved care pathways for companion animals' renal health.
• In January 2025, IDEXX Laboratories introduced IDEXX Cancer Dx, a new blood test developed for the early detection of canine lymphoma. This diagnostic panel was made available for integration into routine wellness screenings, allowing veterinarians to identify lymphoma before the appearance of clinical signs. The test offers qualitative results, including specific B-cell and T-cell phenotype classification. This advancement provides a low-cost option within the global companion animal diagnostics market, aiming to support proactive health management and timely interventions for canine patients.
• In January 2025, Zoetis Inc. officially launched its new Vetscan OptiCell™ point-of-care hematology analyzer to the global market at the Veterinary Meeting & Expo (VMX). This system represents a significant advancement in companion animal diagnostics, being the first cartridge-based, artificial intelligence (AI)-powered tool for veterinary hematology. It delivers complete blood count (CBC) analysis in minutes by combining proprietary microfluidics with AI, providing reference laboratory-quality results directly in veterinary clinics. This technology aims to enhance diagnostic efficiency and facilitate rapid clinical decision-making.
• In 2025, Boehringer Ingelheim initiated a strategic collaboration with Eko Health Inc., a firm recognized for its advancements in artificial intelligence for early heart and lung disease detection. This partnership aimed to bolster canine cardiology diagnostics by integrating Boehringer Ingelheim's specialized expertise with Eko Health's digital stethoscopes and AI technology. The objective was to support earlier detection and treatment for dogs, thereby contributing to improved health outcomes and extended lifespans for companion animals. A dedicated mobile application incorporating this innovative technology was anticipated for release in 2026.

Key Market Players

• DEXX Laboratories, Inc.
• Zoetis Inc.
• Virbac
• Heska Corporation
• Neogen Corporation
• Bio-Rad Laboratories, Inc.
• INDICAL Bioscience GmbH
• Agrolabo SpA
• ID.vet
• bioMérieux S.A.

By Animal Type	By Technology	By Region
Dogs Cats Horses Others	Clinical Biochemistry Clinical Chemistry Analysis Glucose Monitoring Blood Gas & Electrolyte Analysis Immunodiagnostics Hematology Urinalysis Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Companion Animal Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Companion Animal Diagnostics Market, By Animal Type:

• Dogs
• Cats
• Horses
• Others

• Companion Animal Diagnostics Market, By Technology:

• Clinical Biochemistry
• Clinical Chemistry Analysis
• Glucose Monitoring
• Blood Gas & Electrolyte Analysis
• Immunodiagnostics
• Hematology
• Urinalysis
• Others

• Companion Animal Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE